29 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28435528	24	Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.	Kezar Life Sciences
25006746	85	Structure-based design ofß1i orß5i specific inhibitors of human immunoproteasomes.	Leiden Institute of Chemistry and Netherlands Proteomics Centre
24900849	17	Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.	Weill Cornell Medical College
24524217	65	Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.	Hokkaido University
22978849	13	Molecular mechanisms of acquired proteasome inhibitor resistance.	University of California San Diego
19348473	12	Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).	Proteolix
32189500	56	LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.	University of Kentucky
30639896	42	Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.	Hangzhou Institute of Innovative Medicine
31560200	30	Selective Phenylimidazole-Based Inhibitors of the	Weill Cornell Medicine
30611983	48	Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.	Zhejiang University
30380863	196	Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).	Kezar Life Sciences
31521028	67	Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.	Hangzhou Xixi Hospital
30657666	263	Structure-Based Design of Inhibitors Selective for Human Proteasome ?2c or ?2i Subunits.	Leiden Institute of Chemistry and Netherlands Proteomics Centre
31177777	54	Improvement of Asparagine Ethylenediamines as Anti-malarial	Weill Cornell Medicine
31670954	9	The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.	Purdue University
30391816	43	Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.	Zhejiang University
30455150	10	Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.	Kumamoto University
30165344	63	Design, synthesis, and evaluation of cystargolide-based ?-lactones as potent proteasome inhibitors.	New Mexico Institute of Mining and Technology
29339252	124	Structure-based design of human immuno- and constitutive proteasomes inhibitors.	Universit£
29782167	48	Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.	University of Glasgow
2250662	140	Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.	Glaxo Group Research